SEC filings
SEC filings and financial reports.
NÖK files its public reports with the U.S. Securities and Exchange Commission under Regulation A. We encourage investors to read them for detailed information about our operations, financial condition, risk factors and management.
Updated from EDGAR on November 10, 2026.See all filings on EDGAR
Financial reports
Annual reports on Form 1-K and semiannual reports on Form 1-SA, with financial statements.
| Filed | Form | Description | Link |
|---|---|---|---|
| September 28, 2026 | 1-SA | Semiannual report, period ended June 30, 2026 | View |
| April 30, 2026 | 1-K | Annual report, fiscal year ended December 31, 2025 | View |
| September 30, 2025 | 1-SA | Semiannual report, period ended June 30, 2025 | View |
| May 6, 2025 | 1-K | Annual report, fiscal year ended December 31, 2024 | View |
Current reports
Reports on Form 1-U of certain events, generally filed within four business days.
| Filed | Form | Description | Link |
|---|---|---|---|
| July 15, 2026 | 1-U | Current report | View |
| June 3, 2026 | 1-U | Current report | View |
Offering documents
The Regulation A offering statement and related documents.
| Filed | Form | Description | Link |
|---|---|---|---|
| January 3, 2025 | QUALIF | Notice of qualification | View |
| December 23, 2024 | 1-A/A | Amended offering statement | View |
| December 17, 2024 | 1-A/A | Amended offering statement | View |
| December 9, 2024 | 1-A/A | Amended offering statement | View |
| November 26, 2024 | 1-A/A | Amended offering statement | View |
| November 25, 2024 | 1-A/A | Amended offering statement | View |
| November 7, 2024 | 1-A/A | Amended offering statement | View |
| September 26, 2024 | 1-A | Offering statement | View |
Other filings
Notices of exempt offerings and correspondence with SEC staff.
| Filed | Form | Description | Link |
|---|---|---|---|
| May 1, 2026 | D/A | Amended notice of exempt offering (Form D) | View |
| May 1, 2026 | D/A | Amended notice of exempt offering (Form D) | View |
| April 22, 2026 | D/A | Amended notice of exempt offering (Form D) | View |
| April 22, 2026 | D/A | Amended notice of exempt offering (Form D) | View |
| April 22, 2026 | D/A | Amended notice of exempt offering (Form D) | View |
| March 26, 2026 | D | Notice of exempt offering (Form D) | View |
| October 24, 2025 | D | Notice of exempt offering (Form D) | View |
| October 24, 2025 | D | Notice of exempt offering (Form D) | View |
| December 30, 2024 | CORRESP | Correspondence with SEC staff | View |
| December 23, 2024 | CORRESP | Correspondence with SEC staff | View |
| December 20, 2024 | UPLOAD | SEC staff letter | View |
| December 17, 2024 | CORRESP | Correspondence with SEC staff | View |
| December 13, 2024 | UPLOAD | SEC staff letter | View |
| December 9, 2024 | CORRESP | Correspondence with SEC staff | View |
| December 3, 2024 | UPLOAD | SEC staff letter | View |
| November 26, 2024 | CORRESP | Correspondence with SEC staff | View |
| November 25, 2024 | CORRESP | Correspondence with SEC staff | View |
| November 19, 2024 | UPLOAD | SEC staff letter | View |
| November 7, 2024 | CORRESP | Correspondence with SEC staff | View |
| October 23, 2024 | UPLOAD | SEC staff letter | View |
Financial disclosureThe filings on EDGAR are the company's official regulatory disclosures. Any summary on this website should be read together with the full filings and financial statements; if they differ, the SEC filing governs.
Investing in biotechnology companies involves substantial risks, including risks associated with research and development, regulatory approval, financing and commercialization. Investors should review the company'sSEC filings and the risk disclosures in them before making investment decisions. Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any securities, or investment advice. See our legal disclosures and forward-looking statements.